Health Source: New Generation of Glucocorticoids Obtains Approval Notice for Drug Clinical Trials

Health Yuan Announcement: Recently, the company has received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration, allowing the company to conduct clinical trials on a new generation of glucocorticoids. JKN2404 inhalation suspension is a new generation of locally acting, highly selective small molecule glucocorticoid innovative drug independently developed by the company, intended for the treatment of respiratory system diseases such as bronchial asthma.